OTCPK:ASNB

Stock Analysis Report

AdvanSource Biomaterials

Executive Summary

AdvanSource Biomaterials Corporation develops polymer materials for use in the design and development of medical devices used for treating a range of anatomical sites and disease states.

Snowflake

Fundamentals

Good value with acceptable track record.

Share Price & News

How has AdvanSource Biomaterials's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-12.3%

ASNB

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

34.4%

ASNB

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: ASNB exceeded the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: ASNB exceeded the US Market which returned 5.6% over the past year.


Shareholder returns

ASNBIndustryMarket
7 Day-12.3%1.7%2.3%
30 Day-20.8%-1.7%-1.0%
90 Day42.4%-1.7%-0.7%
1 Year34.4%34.4%11.0%10.1%7.9%5.6%
3 Year83.3%83.3%70.4%65.2%45.6%36.3%
5 Year203.3%203.3%128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is AdvanSource Biomaterials's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AdvanSource Biomaterials undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: ASNB ($0.12) is trading below our estimate of fair value ($0.56)

Significantly Undervalued: ASNB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ASNB is good value based on its PE Ratio (5.1x) compared to the Medical Equipment industry average (41.1x).

PE vs Market: ASNB is good value based on its PE Ratio (5.1x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ASNB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ASNB has negative assets, so we can't compare its PB Ratio to the US Medical Equipment industry average.


Next Steps

Future Growth

How is AdvanSource Biomaterials forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AdvanSource Biomaterials has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine whether AdvanSource Biomaterials is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access AdvanSource Biomaterials's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has AdvanSource Biomaterials performed over the past 5 years?

14.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ASNB has become profitable over the past 5 years, growing earnings by 14.6% per year.

Accelerating Growth: ASNB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ASNB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: ASNB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: ASNB has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: ASNB has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is AdvanSource Biomaterials's financial position?


Financial Position Analysis

Short Term Liabilities: ASNB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ASNB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ASNB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ASNB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: ASNB's debt is well covered by operating cash flow (273.6%).

Interest Coverage: ASNB's interest payments on its debt are not well covered by EBIT (2.2x coverage).


Balance Sheet

Inventory Level: ASNB has a high level of physical assets or inventory.

Debt Coverage by Assets: ASNB has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Next Steps

Dividend

What is AdvanSource Biomaterials's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ASNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ASNB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ASNB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ASNB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ASNB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of AdvanSource Biomaterials's salary, the management and board of directors tenure and is there insider trading?

16.8yrs

Average board tenure


CEO

Michael Adams (63yo)

13.2yrs

Tenure

US$336,000

Compensation

Mr. Michael F. Adams has been the Chief Executive Officer and President at AdvanSource Biomaterials Corporation (formerly, Cardiotech International Inc.) since August 7, 2006 and serves as its Secretary an ...


CEO Compensation Analysis

Compensation vs. Market: Michael's total compensation ($USD336.00K) is below average for companies of similar size in the US market ($USD493.00K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Board Age and Tenure

16.8yrs

Average Tenure

70yo

Average Age

Experienced Board: ASNB's board of directors are seasoned and experienced ( 16.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Michael Adams (63yo)

    CEO, President

    • Tenure: 13.2yrs
    • Compensation: US$336.00k
  • Ajay Nagle

    Head of Legal

    • Tenure: 0yrs
  • Khristine Carroll (46yo)

    Executive Vice President of Commercial Operations

    • Tenure: 3.5yrs
    • Compensation: US$226.00k

Board Members

  • Michael Adams (63yo)

    CEO, President

    • Tenure: 13.2yrs
    • Compensation: US$336.00k
  • Mark Tauscher (66yo)

    Director

    • Tenure: 9yrs
    • Compensation: US$4.00k
  • Michael Barretti (74yo)

    Director

    • Tenure: 21.8yrs
    • Compensation: US$4.00k
  • William O'Neill (76yo)

    Chairman of the Board

    • Tenure: 13.2yrs
    • Compensation: US$5.00k

Company Information

AdvanSource Biomaterials Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AdvanSource Biomaterials Corporation
  • Ticker: ASNB
  • Exchange: OTCPK
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.600m
  • Shares outstanding: 21.49m
  • Website: https://www.advbiomaterials.com

Number of Employees


Location

  • AdvanSource Biomaterials Corporation
  • 229 Andover Street
  • Wilmington
  • Massachusetts
  • 1887
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ASNBOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 1996

Biography

AdvanSource Biomaterials Corporation develops polymer materials for use in the design and development of medical devices used for treating a range of anatomical sites and disease states. It offers polymers ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:10
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.